Italy – Refuse disposal and treatment – SERVIZIO GESTIONE DEI RIFIUTI SPECIALI PERICOLOSI E NON E PER I SERVIZI ECOLOGICI DEL CENTRO RICERCHE DELLA CASACCIA E DELLA SEDE LEGALE ENEA

Italy – Refuse recycling services – Procedura Aperta, suddivisa in 2 (due) Lotti, per l'affidamento del servizio di trattamento e recupero dei rifiuti in legno provenienti dai centri di raccolta di AMA S.p.A., dal servizio di raccolta differenziata tramite noleggio cassoni c/o le grandi utenze, dalle operazioni di rimozione rifiuti e/o dalle richieste di viaggi a pagamento, conferiti da AMA S.p.A. e/o per conto di AMA S.p.A., per un

Italy – Building-cleaning services – PROCEDURA APERTA, SUDDIVISA IN TRE LOTTI, PER L’AFFIDAMENTO TRIENNALE DEI SERVIZI INTEGRATI PRESSO LE SEZIONI DELL’ISTITUTO NAZIONALE DI GEOFISICA E VULCANOLOGIA (INGV): LOTTO 1_ SEZIONE DI NAPOLI (SEDI DI NAPOLI: OSSERVATORIO VESUVIANO-Via DIOCLEZIANO E SEDE di ERCOLANO); LOTTO 2_SEZIONE DI CATANIA – OSSERVATORIO ETNEO; LOTTO 3_SEZIONE IRPINIA

Italy – Cleaning and sanitation services – Servizi di pulizia, sanificazione ambientale e prestazioni accessorie a ridotto impatto ambientale presso gli stabili del "Polo Tuscolano" siti in Roma

Italy – Cleaning and sanitation services – APPALTO SERVIZI DI PULIZIA DEGLI UFFICI DEGLI ORGANISMI DELLA POLIZIA DI STATO DI CATANZARO E PROVINCIA DURATA TRIENNALE

Italy – Snow-clearing services – PROCEDURA APERTA AI SENSI DELL’ARTICOLO 71 DEL D.LGS. N. 36/2023 PER L’AFFIDAMENTO DEL SERVIZIO DI SGOMBERO NEVE, TRATTAMENTO ANTIGHIACCIO E MANTENIMENTO DELLA VIABILITA’ COMUNALE PER LE STAGIONI INVERNALI 2026/2027 - 2027/2028 – 2028/2029 IN COMUNE DI VALFURVA.

Established by Congress in fiscal year (FY) 1997, the Habitat Conservation Plan (HCP) Land Acquisition Grant program was designed to reduce conflicts between the conservation of listed species and competing land uses on specific parcels of land associated with approved and permitted HCPs. Under this program, the U.S. Fish and Wildlife Service (FWS) provides matching grants to State agencies in support of land acquisition projects that will conserve species habitat in perpetuity through fee simple acquisition or the acquisition of permanent conservation easements. FWS considers the use of Federal acquisition dollars by States for habitat protection associated with HCPs to be an important and effective mechanism to promote species recovery, prevent extinction, and preclude the need to list species under the Endangered Species Act (ESA) in the future. All land acquired through these grants complements, but does not replace, the mitigation, minimization, and/or monitoring commitments of the HCP. Thus, this work is additive to the conservation commitments entered into when HCPs are permitted and serves as a meaningful way to leverage non-Federal investment in species recovery and connect conservation lands across the landscape.

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

This program is not open to the public. Eligibility is determined by federal statute. Applications can only be accepted from the designated state authority or agency.

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…